National Guideline Clearinghouse | Enzalutamide for metastatic hormone-relapsed prostate cancer previously treated with a docetaxel-containing regimen.

full-text ►

National Guideline Clearinghouse | Enzalutamide for metastatic hormone-relapsed prostate cancer previously treated with a docetaxel-containing regimen.



National Institute for Health and Care Excellence (NICE)

Guideline Title

Enzalutamide for metastatic hormone-relapsed prostate cancer previously treated with a docetaxel-containing regimen.

Bibliographic Source(s)

National Institute for Health and Care Excellence (NICE). Enzalutamide for metastatic hormone-relapsed prostate cancer previously treated with a docetaxel-containing regimen. London (UK): National Institute for Health and Care Excellence (NICE); 2014 Jul. 59 p. (Technology appraisal guidance; no. 316).

Guideline Status

This is the current release of the guideline.

This guideline meets NGC's 2013 (revised) inclusion criteria.